To explore the differences in the clinical features, treatment responses, and outcomes among children, adolescents, and adults with chronic myeloid leukemia in the chronic phase (CML-CP) receiving imatinib as first-line therapy. Data from children (0–8 years for girls and 0–10 years for boys), adolescents (9–19 years for girls and 11–19 years for boys), and adults (age ≥ 20 years) with newly diagnosed CML-CP receiving imatinib as first-line therapy between 2006 and 2019 were retrospectively reviewed. In total, 135 children (cohort 1), 189 adolescents (cohort 2), and 658 adults (cohort 3: age 20–39 years, n = 305; cohort 4: age 40–59 years, n = 270; and cohort 5: age 60–83 years, n = 83) were included in this study. When compared with children, adolescents showed a significantly higher white blood cell count (P = 0.033) and basophil percentage in peripheral blood (P = 0.002) and a significantly higher prevalence of splenomegaly (P = 0.004). Both children and adolescents presented with more aggressive clinical features than adults. During median follow-ups of 28 months (range, 3–161 months) in children, 33 months (range, 3–152 months) in adolescents, and 48 months (range, 3–157 months) in adults, multivariate analysis showed that children and adolescents had higher probabilities of achieving complete cytogenetic response, major molecular response, and molecular response4.5. Notably, compared with not only adults (cohort 3 vs. cohort 1: HR = 2.03 [1.03, 3.98], P = 0.040; cohort 4 vs. cohort 1: HR = 2.15 [1.07, 4.33], P = 0.033; cohort 5 vs. cohort 1: HR = 4.22 [1.94, 9.15], P < 0.001) but also adolescents (cohort 2 vs. cohort 1: HR = 2.36 [1.18, 4.72], P = 0.015), children had significantly longer failure-free survival. Age was not associated with progression-free survival or overall survival. Although they exhibited more aggressive clinical features at diagnosis, both children and adolescents achieved superior treatment responses than adults. Adolescents showed even more adverse features and a poor FFS than children.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Höglund M, Sandin F, Simonsson B (2015) Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol 94(2):241–247
Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872–884
Ries LAG SM, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR (eds) (1999) Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995, National Cancer Institute, SEER Program. NIH Pub. No. 99–4649. Bethesda, MD
Chen Y, Wang H, Kantarjian H et al (2013) Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma 54(7):1411–1417
Hijiya N, Suttorp M (2019) How I treat chronic myeloid leukemia in children and adolescents. Blood 133(22):2374–2384
Athale U, Hijiya N, Patterson BC et al (2019) Management of chronic myeloid leukemia in children and adolescents: recommendations from the Children’s Oncology Group CML Working Group. Pediatr Blood Cancer 66(9):e27827
Hijiya N, Schultz KR, Metzler M et al (2016) Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood 127(4):392–399
Castagnetti F, Gugliotta G, Baccarani M et al (2015) Differences among young adults, adults and elderly chronic myeloid leukemia patients. Annals of oncology : official Ann Oncol 26(1):185–192
Kalmanti L, Saussele S, Lauseker M et al (2014) Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Ann Hematol 93(1):71–80
Pemmaraju N, Kantarjian H, Shan J et al (2012) Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica 97(7):1029–1035
Millot F, Guilhot J, Baruchel A et al (2014) Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study. Blood 124(15):2408–2410
Giona F, Putti MC, Micalizzi C et al (2015) Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. Br J Haematol 170(3):398–407
Gurrea Salas D, Glauche I, Tauer JT et al (2015) Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients? Ann Hematol 94(8):1363–1371
Irwin CE Jr (2011) Chapter 63. Somatic Growth and Development. In: Rudolph CD, Rudolph AM, Lister GE et al (eds) Rudolph’s Pediatrics, 22e. The McGraw-Hill Companies, New York
Shima H, Tokuyama M, Tanizawa A et al (2011) Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr 159(4):676–681
Millot F, Guilhot J, Baruchel A et al (2014) Growth deceleration in children treated with imatinib for chronic myeloid leukaemia. Eur J Cancer 50(18):3206–3211
Qin Y-Z, Jiang Q, Jiang H et al (2013) Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level? Leuk Res 37(9):1035–1040
Hochhaus A, Baccarani M, Silver RT et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966–984
Suttorp M, Millot F, Sembill S et al (2021) Definition, epidemiology, pathophysiology, and essential criteria for diagnosis of pediatric chronic myeloid leukemia. Cancers (Basel) 13(4):798
Millot F, Traore P, Guilhot J et al (2005) Clinical and Biological Features at Diagnosis in 40 Children With Chronic Myeloid Leukemia. Pediatrics 116(1):140–143
Krumbholz M, Karl M, Tauer JT et al (2012) Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia. Genes Chromosom Cancer 51(11):1045–1053
Baccarani M, Castagnetti F, Gugliotta G et al (2019) The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia An international overview. Leukemia 33(5):1173–1183
Sembill S, Göhring G, Schirmer E, Lutterloh F, Suttorp M, Metzler M, Karow A (2021) Paediatric chronic myeloid leukaemia presenting in de novo or secondary blast phase - a comparison of clinical and genetic characteristics. Br J Haematol. 193(3):613-618
Millot F, Guilhot J, Suttorp M et al (2017) Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents. Haematologica 102(10):1704–1708
Suttorp M, Schulze P, Glauche I et al (2018) Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. Leukemia 32(7):1657–1669
Giona F, Malaspina F, Putti MC et al (2020) Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia. Br J Haematol 188(6):e101–e105
Millot F, Baruchel A, Guilhot J et al (2011) Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol 29(20):2827–2832
de Bruijn CMA, Millot F, Suttorp M et al (2019) Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the STOP IMAPED study. Br J Haematol 185(4):718–724
Champagne MA, Fu CH, Chang M et al (2011) Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer 57(1):56–62
Rossoff J, Huynh V, Rau RE et al (2020) Experience with ponatinib in paediatric patients with leukaemia. Br J Haematol 189(2):363–368
Gore L, Kearns PR, de Martino ML et al (2018) Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial. J Clin Oncol 36(13):1330–1338
Millot F, Maledon N, Guilhot J et al (2019) Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemia. Eur J Cancer 115:17–23
Cai Y, Liu C, Guo Y et al (2021) Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China. Int J Hematol 113:413–421
Millot F, Claviez A, Leverger G et al (2014) Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase. Pediatr Blood Cancer 61(2):355–357
Rohan JM, Fukuda T, Alderfer MA et al (2017) Measuring medication adherence in pediatric cancer: an approach to validation. J Pediatr Psychol 42(2):232–244
Suttorp M, Millot F (2010) Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. Hematology 2010(1):368–376
The authors would like to thank Professor Meinolf Suttorp who kindly reviewed the typescript and the American Journal Experts (www.journalexperts.com) that provided editorial assistance.
This study was funded by the National Natural Science Foundation of China (No. 81770161 and No. 81970140).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Xuelin Dou, Fangyuan Zheng, and Liqiang Zhang contributed equally to this article
About this article
Cite this article
Dou, X., Zheng, F., Zhang, L. et al. Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study. Ann Hematol 100, 2215–2228 (2021). https://doi.org/10.1007/s00277-021-04544-6
- Chronic myeloid leukemia